Targeting a specific protein pathway to improve melanoma treatment
Official title: Targeting the SKP2 Axis for Anti-melanoma Therapy
Funded at Beth Israel Deaconess Medical Center · NIH-11123811 · Data updated 2026-11-12
This study is looking at a protein called SKP2 to see how it affects melanoma, a serious type of skin cancer, with the goal of finding better treatment options that are more suited to individual patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 4, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $395,509 |
| NIH project number | 1R01CA291991-01A1 |
| Project ID | NIH-11123811 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with melanoma, particularly those with specific genetic alterations in their tumors.
✕Less likely to help
Patients with non-melanoma skin cancers or those whose melanoma has already progressed beyond treatment options may not benefit from this research.
What this research studies
This research investigates the role of the SKP2 protein in melanoma, a highly aggressive form of skin cancer. By analyzing how SKP2 and other related proteins contribute to the development and progression of melanoma, the research aims to identify new therapeutic targets. The approach includes studying the molecular mechanisms involved in melanoma and exploring how targeting these pathways can enhance treatment effectiveness. Patients may benefit from improved treatment options that are tailored to their specific tumor characteristics.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for melanoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promising results in targeting similar protein pathways in cancer treatment, indicating that this approach may be effective.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Inuzuka, Hiroyuki — Beth Israel Deaconess Medical Center
- Study coordinator: Inuzuka, Hiroyuki
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.